An observational study in Kidney Cancer and Lung Cancer, sponsored by University Hospital, Tours. Completed at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-12.
Sponsored by University Hospital, Tours · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 108 studies in Kidney Neoplasms with a site in France — 31 open to participants now, 36 under way, 4 of them phase 3. Kidney Neoplasms · France.
Among the 108 studies in Kidney Neoplasms with a site in France, this one is the 23rd largest by enrollment of the 30 observational ones that give a count, is one of 9 that started in 2018, is one of 30 observational ones, and was the 55th registered.
969 studies on the registry are indexed under Kidney Neoplasms; 209 are open to participants now.
Browse Kidney Neoplasms studies →31 of the 108 studies in Kidney Neoplasms with a site in France are open now. Recruiting first, the newest first:
Mark C Burgmans, MD PhD · Sites in France, Netherlands
Ages 18+
Institut Paoli-Calmettes · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
European Organisation for Research and Treatment of Cancer - EORTC · Sites in France
Ages 18–100
Bristol-Myers Squibb · Sites in France, United States, Canada and 2 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 172 Kidney Neoplasms studies recruiting now, 132 (77%) set no upper age limit and 15 (9%) stop at 75 or younger; 20 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
108 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 26 · Phase 3 15 · Phase 4 3
First in 1993; this study’s year is marked. 9 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is below the median of 211 across 215 observational studies indexed under Kidney Neoplasms.
Median enrollment 100 across the 78 interventional studies, 163 across the 30 observational. Of the 58 that completed or were terminated, 17 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 108 have an industry lead sponsor. The 10 most frequent:
University Hospital, Tours is the lead sponsor of 309 studies on the registry; 81 are open to participants now.
University Hospital, Tours has 1 study filed under Kidney Neoplasms — fewer than ten, so there is no comparison to draw.
7 of the studies in Kidney Neoplasms with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03185039Institut Paoli-CalmettesPredictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents | 2026-12-19 |
| NCT07739121Assistance Publique - Hôpitaux de ParisBenchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations | 2026-12-31 |
| NCT06026410Kura Oncology, Inc.KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | 2027-01 |
| NCT05433142Xencor, Inc.Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | 2027-02 |
| NCT05241561Centre Hospitalier Universitaire de BesanconCabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients | 2027-03 |
Add all 7 to your calendar (.ics) → With an account.
Among the 108 studies in Kidney Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess the relationship between progression free survival of patients treated with nivolumab for metastatic non small cell lung carcinoma or a metastatic renal cell carcinoma and nivolumab blood concentration.
Collection of standard data prospectively.
Nivolumab is a monoclonal antibody used for the treatment of non small cell lung carcinoma and renal cell carcinoma. Huge variability exists between patients treated by nivolumab in terms of efficacy and side effects. Like others monoclonal antibodies, a relation between concentration and effects of nivolumab may exist.
The aim of this study is to assess the relationship between blood concentration of nivolumab and progression free survival, overall survival and side effects on the one hand, and on the other to describe pharmacokinetic of nivolumab
Patients treated with nivolumab at CHRU of Tours for squamous or non squamous non small cell lung cancer stage IV or renal cell carcinoma stage IV
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients under nivolumab (Opdivo 10 MG/ML) for the treatment of non small cell lung carcinoma or renal cell carcinoma. Measure of nivolumab residual concentration 14 days after administration of nivolumab and just before the new perfusion.
Other: Pharmacokinetic of Nivolumab
Nivolumab residual concentration is measured 14 days after administration of nivolumab 3 mg/kg as an intravenous infusion just before the new administration.
Also known as: Opdivo
This study also gives Nivolumab. No intervention listed here names it: that was found by reading the record.
Progression free survival
Association between nivolumab concentration and progression free survival : time from start of nivolumab treatment to progression
Time frame: Up to one year
Overall survival
Association between nivolumab concentration and overall survival : time from start of nivolumab treatment to death
Time frame: Up to one year
Target concentration
Determination of nivolumab concentration associated with clinical benefit (complete response + partial response + stable disease)
Time frame: 14 days
Side effects
Association between nivolumab residual concentration and side effects
Time frame: 14 days
Nivolumab PK parameters : distribution volume
Nivolumab residual concentrations will be measured each 14 days until the end of the study (up to one year).
Time frame: Baseline up to one year
Nivolumab PK parameters : clearance
Nivolumab residual concentrations will be measured each 14 days until the end of the study (up to one year).
Time frame: Baseline up to one year
Ran from Jan 2018 to primary completion in Dec 2018, 10 months.
Of 89 non-industry observational studies under Kidney Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34. This study's 10 months is below that.
Counting every sponsor, half of 107 studies reached it within 74 months; a quarter within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.